Stay updated on PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4, indicating a new page release in the system. The change does not alter the visible content or study data on the page.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page’s footer revision/version was updated from v3.5.2 to v3.5.3, indicating a minor update to the site itself rather than a change to the clinical trial study content.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check71 days agoChange DetectedPage revision updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check78 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check107 days agoChange DetectedThe page now displays a new revision label: Revision: v3.4.2. This is a minor meta-update and does not alter study details or eligibility information.SummaryDifference0.1%

Stay in the know with updates to PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.